Teva Launches Zecuity Transdermal Treatment for Migraine

Share this content:
Teva Launches Zecuity Transdermal Treatment for Migraine
Teva Launches Zecuity Transdermal Treatment for Migraine

Teva CNS announced the launch of Zecuity (sumatriptan iontophoretic transdermal system) indicated for the treatment of migraine with or without aura in adults. Zecuity was initially approved by the Food and Drug Administration (FDA) in January 2013.

Zecuity delivers 6.5mg of sumatriptan over 4 hours and can be applied on 2 interchangeable sites: upper arm or thigh. The drug is delivered through the skin via a low electrical current.

Sumatriptan is a serotonin (5HT) 1B/1D receptor agonist that exerts its therapeutic effects by binding to 5HT 1B/1D receptors located on intracranial blood vessels and sensory nerves of the trigeminal system. This results in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.

Zecuity is available as a single-use 6.5mg/4hrs transdermal system in 4-count cartons.

For more information call (888) 483-8279 or visit Zecuity.com.

You must be a registered member of Neurology Advisor to post a comment.
close

Next Article in Migraine and Headache

Sign Up for Free e-newsletters



CME Focus